Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
about
Energy disruptors: rising stars in anticancer therapy?Advances in targeting signal transduction pathwaysInsulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer RiskMesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential.Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling.Hyperglycemia, a neglected factor during cancer progressionAMPK activation--protean potential for boosting healthspan.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Understanding the benefit of metformin use in cancer treatment.Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancerMetformin ameliorates the Phenotype Transition of Peritoneal Mesothelial Cells and Peritoneal Fibrosis via a modulation of Oxidative Stress.Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancerRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Novel clinical therapeutics targeting the epithelial to mesenchymal transitionThe T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cellsKetones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-GenomicsGerosuppressant metformin: less is moreLin28 induces epithelial-to-mesenchymal transition and stemness via downregulation of let-7a in breast cancer cells.Metformin inhibits the IL-6-induced epithelial-mesenchymal transition and lung adenocarcinoma growth and metastasis.Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case SeriesMetformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancerHyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue.Recent progress in targeting cancer.Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progressionMetformin: multi-faceted protection against cancer.Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models.Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis.Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary TumorigenesisCancer risk in HBV patients with statin and metformin use: a population-based cohort study.Combination Twist1 and CA15-3 in axillary lymph nodes for breast cancer prognosis.AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition.Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cellsEpithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineBasal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Metformin targets ovarian cancer stem cells in vitro and in vivo.A comparison of epithelial-to-mesenchymal transition and re-epithelializationThe impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines
P2860
Q26771300-58ECB9E5-DA5B-4B28-9094-C51D2D4B6AEFQ27686983-D7304ECC-7F70-4933-9CE6-53A335D5118BQ28072521-445619EB-9E27-4628-801E-576C70DEAD4DQ31158116-ECC5FAF7-DB44-4B00-9DBC-91B7BFACE228Q33591312-7BFB89EA-EF78-410D-830E-A5DF40CD1AECQ33594115-1C308A2E-6496-40F6-BC76-7B9FF506B3F5Q33689169-F2FD5E5F-9736-4607-9B48-881BA973C1F9Q33751263-1E4F2F8E-0048-494C-BEC1-A24FFA1AD14DQ33864199-4C971497-B0F2-4DA7-96D7-734B06EDB0FCQ33882085-10EDD0BD-C0C2-4370-ADC4-2D2313A6209AQ33915937-19D8D064-DAE7-4DF8-AF9D-124BD4EA0782Q34168398-006D912E-7EE3-4AE4-9FBB-AB64C9D948A7Q34307356-A987CDA1-7857-40C4-8907-D55E2317C713Q34345818-6F21D6BC-FCF8-42E4-85CE-55B4047E49E0Q34397165-33D6558B-44AF-4CE7-B52C-F3CDF6DC526FQ35051171-C0B10690-A78A-4E39-A5FA-01E7F7D5822BQ35052060-31C60EDF-DBF2-4EDC-8E54-7FA80D6BA2FDQ35070771-B107DCC3-E42C-40C3-B44D-1382973315DEQ35161856-42DA74AF-4DA5-44E1-85A1-40D9917CE189Q35226909-5DC11706-A254-487D-A2F5-92303688215BQ35645149-483BA967-3505-4557-A147-173ACAC874FBQ35737581-79CE3E8E-D793-4F4C-B6CB-28D180D61BD3Q35740782-BED65A86-5051-4991-893C-86579E867BE8Q35754181-5A87623F-A874-4280-8464-DA34F5317121Q35764409-F957759B-B11D-4B05-BA79-04D4BA359B41Q35770306-EF30D310-6A6E-4745-AF05-A15AFE759B07Q35835794-08974736-8D75-44A8-907A-D72CB4224DB4Q36000472-C6BE34DD-B001-4EB7-96E9-6381116D3DA3Q36078840-026B6A0A-54B9-4547-8AD8-75BEB77B143AQ36152361-66D2EF1D-B155-42E1-B0EE-E97562D015B4Q36256977-F56B6180-E598-43B9-84A2-3DE1C3122071Q36316820-54FBDFE4-F728-462E-8C79-0E7E6409E211Q36419610-744E4DE8-3663-4919-940F-4C9BA66FEC72Q36426509-BF59306C-C7E3-411F-87E2-0FACE8DE80F9Q36546685-7FA9EB18-BEDB-459A-AD07-D25CE9384BC5Q36556350-3B8DF6F7-51CF-4A36-B80E-932846EC6D3AQ36618624-7BF792AE-B934-4040-BBF0-AB6DEC312BD8Q36632485-2F7E5EA7-7B00-4504-8C7C-ED0E1DB3FD4AQ36678367-9B0F7FE8-DD45-475A-991F-DD203ED9F20FQ36742179-03CC3244-76B7-4EAE-875E-D328FD390A08
P2860
Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Metformin regulates breast can ...... hymal transition (EMT) status.
@en
Metformin regulates breast can ...... thelial-mesenchymal transition
@nl
type
label
Metformin regulates breast can ...... hymal transition (EMT) status.
@en
Metformin regulates breast can ...... thelial-mesenchymal transition
@nl
prefLabel
Metformin regulates breast can ...... hymal transition (EMT) status.
@en
Metformin regulates breast can ...... thelial-mesenchymal transition
@nl
P2093
P1433
P1476
Metformin regulates breast can ...... chymal transition (EMT) status
@en
P2093
Alejandro Vazquez-Martin
Begoña Martin-Castillo
Cristina Oliveras-Ferraros
Javier A Menendez
Silvia Cufí
Sonia Del Barco
P304
P577
2010-09-25T00:00:00Z